Amonafide
Clinical data
Trade namesXanafide, Quinamed
ATC code
  • none
Identifiers
  • 5-amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H17N3O3
Molar mass299.330 g·mol−1
3D model (JSmol)
  • O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
  • InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3 checkY
  • Key:UPALIKSFLSVKIS-UHFFFAOYSA-N checkY
  (verify)

Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.[1][2]

It was being developed as an anti-cancer therapy by Antisoma.[3]

As of 2008, it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).[4] In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.

See also

References

  1. ↑ Allen SL, Lundberg AS (July 2011). "Amonafide: a potential role in treating acute myeloid leukemia". Expert Opinion on Investigational Drugs. 20 (7): 995–1003. doi:10.1517/13543784.2011.585756. PMID 21591994.
  2. ↑ Freeman CL, Swords R, Giles FJ (February 2012). "Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?". Expert Review of Hematology. 5 (1): 17–26. doi:10.1586/ehm.11.68. PMID 22272701.
  3. ↑ "Antisoma's Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial". Genetic Engineering & Biotechnology News. 29 March 2010. Archived from the original on 1 April 2010.
  4. ↑ Clinical trial number NCT00715637 for "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study" at ClinicalTrials.gov

Public Domain This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.